US Stock MarketDetailed Quotes

APLS Apellis Pharmaceuticals

Watchlist
  • 27.980
  • +0.720+2.64%
Close Nov 1 16:00 ET
  • 27.980
  • 0.0000.00%
Post 20:02 ET
3.41BMarket Cap-10286P/E (TTM)

Apellis Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Apellis Pharmaceuticals Q3 2024 Estimates Date

Currency：USDNov 5, 2024

Estimate YoY
Revenue
199.82M
+81.00%
EPS
-0.31
+73.23%
Analyst Rating
Buy

Nov 3, 2024

Apellis Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 19 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 213.078M--
Nov 5, 20242024/Q3-- / 199.824M--
Aug 1, 20242024/Q2199.685M / 191.306M--
May 7, 20242024/Q1172.325M / 164.259M--
Feb 27, 20242023/Q4146.377M / 143.592M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 213.078M--
Nov 5, 20242024/Q3-- / 199.824M--
Aug 1, 20242024/Q2199.685M / 191.306M--
May 7, 20242024/Q1172.325M / 164.259M--
Feb 27, 20242023/Q4146.377M / 143.592M--

Unlock Free Earnings Estimates

Apellis Pharmaceuticals Earnings Reports

  • Apellis Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

    Aug 1 07:07 ET

  • Apellis Pharmaceuticals | 10-Q: Q1 2024 Earnings Report

    May 7 07:04 ET

  • Apellis Pharmaceuticals | 10-K/A: Annual report (Amendment)

    Feb 29 17:15 ET

  • Apellis Pharmaceuticals | 10-K: FY2023 Annual Report

    Feb 27 07:05 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 3, 2024

    Buy

    • Buy

      73.68%

    • Hold

      26.32%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data

    Concept Gene Editing
    Gene Editing
    Intraday+0.75%